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Abstract
Current methods for assessing clinical outcomes in COPD mainly rely on physiological tests combined with the use of 
questionnaires. The present review considers commonly used outcome measures such as lung function, health status, 
exercise capacity and physical activity, dyspnoea, exacerbations, the multi-dimensional BODE score, and mortality. 
Based on current published data, we provide a concise overview of the principles, strengths and weaknesses, and 
discuss open questions related to each methodology. Reviewed is the current set of markers for measuring clinically 
relevant outcomes with particular emphasis on their limitations and opportunities that should be recognized when 
assessing and interpreting their use in clinical trials of COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous, multi-component disease associated with
significant clinical burden. Though the presence of air-
flow limitation is well recognised as the pathophysiologi-
c a l  b a s i s ,  C O P D  a s  a  c o m p l e x  d i s o r d e r  r e q u i r e s  a
multifaceted approach with regard to clinical assessment
and response to therapy. This has prompted an intense
search for clinical trial endpoints that may adequately
reflect the success or failure of treatment. Current meth-
ods for assessing COPD progression mainly rely on lung
function tests with a particular focus on forced expiratory
volume in 1 second (FEV1). However, clinical and patient-
reported outcome measures such as dyspnoea, exercise
capacity, physical activity, exacerbations, health status
and mortality have been recognized and applied as an
essential part of the clinical assessment of COPD beyond
FEV1 measurements [1,2] (figure 1).
In recent years, a profound analysis of available out-
comes and markers has been provided by the scientific
community [3,4]. The objective of this review is to pro-
vide a concise overview of the feasibility, strengths and
limitations of major outcome measures commonly
applied in current COPD trials.
Lung function: forced expiratory volume in 1 second (FEV1)
Relevance
It is well established that patients with COPD lose lung
function at a steeper rate than subjects without COPD.
Post-bronchodilator forced expiratory volume (FEV1) is
the single most important marker to determine severity
and treatment algorithms in COPD. The decline of FEV1
over time has been traditionally used to indicate disease
progression.
Measures
The diagnosis, staging and treatment of COPD in current
guidelines is based on the fixed ratio of FEV1/FVC
(forced vital capacity) and the percentage predicted FEV1
value.
The methodology for measuring forced expiratory
maneuvers by spirometry has been standardized by ATS/
ERS [5]. Specific training to yield reproducible and reli-
able results is mandatory.
Strengths
•FEV1 and FVC measurements are highly reproducible if
performed adequately.
•Reduction in lung function is a risk factor for all cause
and cardiovascular mortality [6-8], and impaired health
status [9].
•Spirometry supports confirmatory detection of early
stages of COPD when respiratory symptoms are often
* Correspondence: r.buhl@3-med.klinik.uni-mainz.de
1 Pulmonary Department, University Hospital, Johannes Gutenberg-University, 
Mainz, Germany
Full list of author information is available at the end of the articleGlaab et al. Respiratory Research 2010, 11:79
http://respiratory-research.com/content/11/1/79
Page 2 of 11
absent, thus creating the opportunity of early interven-
tion [10].
Limitations
•FEV1 measurements are based on an artificial manoeu-
vre and do not always correlate with clinically relevant
outcomes such as dyspnoea, health status, exercise capac-
ity, or exacerbations [4,11].
•Patients with similar FEV1  may represent different
underlying phenotypes.
•Reference equations for lung function by European
Community for Coal and Steel are disputed and limited
in predicting lung function in the general population [12].
•Changes in lung volumes can occur without concomi-
tant changes in FEV1 and are more closely related than
FEV1 changes to exercise performance [13].
•No minimal important difference (MID) has been
established yet. It was suggested that an appropriate
range of values for the MID for FEV1 might be 100-140
mL [4] but the MID for FEV1 remains poorly defined for
COPD [14].
Open Questions and Outlook
FEV1, while a crucial marker, is far from being the only
measure to comprehensively characterize patients with
COPD. Additional outcome measures are usually needed
to assess the clinical benefit of therapeutic agents. The
relationships between changes in airway structure and
measures of lung function require further investigation.
Lung volumes
Relevance
Changes in absolute lung volumes can occur in COPD
patients even in the absence of FEV1 changes. Progressive
hyperinflation due to airflow limitation and loss of lung
elastic recoil not only increases the work required during
inspiration but also profoundly decreases the ventilatory
reserve and increases the sense of effort and dyspnoea
[15].
The assessement of absolute lung volumes has been
standardized but is technically more demanding than
simple spirometry. Specific training to yield reproducible
and reliable results is essential.
Measures
Static lung hyperinflation and its increase during exercise
(dynamic hyperinflation) are measured as elevations of
total lung capacity (TLC), functional residual capacity
(FRC), residual volume (RV) and as a decrease in inspira-
tory capacity (IC). The variability of lung volume mea-
surements has been reviewed elsewhere [16].
Strengths
•Indices of dynamic hyperinflation correlate better than
FEV1  with activity limitation and exertional dyspnoea
[13,15] and pharmacological and surgical lung volume
reduction have been associated with improvements in
exercise performance and dyspnoea [17,18].
Figure 1 Outcome measures relevant for the evaluation of COPD management.
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•A severely reduced IC/TLC ratio with a threshold
value of 25% has been shown to predict mortality in
COPD patients [19].
Limitations
•Body plethysmography remains the gold standard for
the measurement of lung volumes such as TLC, FRC and
RV. Spirometrically derived assessments of lung hyperin-
flation are more difficult to interpret in the absence of
simultaneous bodyplethysmographic volume measure-
ments to rule out a concomitant restrictive ventilatory
disorder [15].
•The reproducibility of FRC, IC and RV in absolute val-
ues has yet to be demonstrated. Measurement of IC alone
is not a reliable marker of lung hyperinflation and does
not consistently reflect changes in FRC or TLC [15].
•Neither a standardized classification for the assess-
ment of severity of hyperinflation nor a MID have been
established yet. In practice, values of RV, TLC and FRC
exceeding 120-130% of the predicted value are regarded
to be clinically relevant, but these cut-offs are not vali-
dated.
•The natural course of dynamic hyperinflation in
COPD is unknown and seems likely to be highly variable
among COPD patients [15].
Open Questions and Outlook
In the absence of any consensus on the definition and/or
severity of hyperinflation, it has been proposed that
hyperinflation - preferentially expressed as % predicted-
should be specified in terms of the volume compartment
referred to and the measuring method used [12]. So far,
there have been no studies aimed at exploring the longi-
tudinal course of dynamic hyperinflation and its impact
on the course of the disease in COPD patients.
Exercise Capacity and Physical Activity
Relevance
Reduced exercise capacity is considered to be a conse-
quence of airflow obstruction, primarily because of
dynamic hyperinflation occurring during exercise.
Reduced physical activity of patients is a result of COPD,
but at the same time promotes worsening and progres-
sion of the disease [20].
Measures
There are different approaches to determine the exercise
capacity or activity levels of COPD patients (table 1):
Higher exercise tolerance measured via laboratory or
field tests can be translated to higher levels of activity. In
addition, physical activity during daily life can be assessed
directly by measuring energy expenditure or by mechani-
cal assessment of movement.
Exercise Capacity
6-Minute Walk Test (6MWT)
Measurement of the distance walked during a 6-minute
period on a level surface [21]. The principal outcome of
this self-paced test is the distance covered. The MID is
estimated to be 54-80 meters [27].
Strengths
•6MWT is relatively simple to perform and well toler-
ated.
•6MWT reflects everyday life-like activity.
•6MWT is validated and standardized [28].
•The test results correlate with lung function, health
status, and maximal VO2 [29], and have shown to be pre-
dictive for mortality [30].
Limitations
•There are many sources of variability, e.g. patient's moti-
vation, weight, height, age, sex, co-morbidities, and day-
to-day variability [28].
•6MWT was significantly reduced only in COPD
patients with GOLD stages III and IV [26,31].
•Assessment of the 6MWT is associated with spatial
requirements and is personnel- and time-consuming.
•Standards of 6MWT are not always realisable. This
might influence the results, e.g. shorter corridors reduce
the distance covered because of time-consuming change
in direction.
•Learning effect: Walking distance is up to 17% higher
for a second test performed a day later [28].
Table 1: Different methods to determine exercise capacity or activity levels in COPD
Measure Reference
field tests to determine exercise capacity 6-Minute Walk Test [21]
Shuttle Walk Test [22,23]
laboratory tests to assess exercise capacity bicycle ergometer [24]
treadmill [25]
assessment of activity levels accelerometer [26]Glaab et al. Respiratory Research 2010, 11:79
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Shuttle Walk Test (SWT)
There are two forms of assessment: In the Incremental
Shuttle Walk Test, walking speed is set by the frequency
of an acoustic signal. The frequency increases progres-
sively until patients can no longer pick up the pace. The
principal outcome is the distance covered. The MID is
estimated to be 47.5 meters [32].
The Endurance Shuttle Walk Test has been developed
to determine sub-maximal exercise capacity with the
acoustic signal frequency being constant throughout the
walk [23]. The principal outcome is the duration of exer-
cise. No MID has yet been described.
Strengths
•SWT is relatively simple to perform and well-tolerated.
•Learning effects are minimal.
•Walking pace is externally controlled.
Limitations
•Instructions for SWT are time consuming.
•The test is less extensively validated than the 6MWT.
Solid evidence for validity still has to be provided [27,33].
•SWT does not reflect common daily activities that
require endurance and pacing.
Ergometry
To evaluate the exercise response, bicycle-ergometer or
treadmill are commonly used in two different test modes.
In incremental-workload tests, work-rate is increased
progressively as a mild continuous ramp under computer
control with the principal outcome being the distance
covered. Alternatively, constant-workload tests have been
performed at sub-maximal levels of exercise intensity
which is typically set between 75% and 85% of the maxi-
mum workload during incremental tests [20]. The princi-
pal outcome is the duration of workload.
Reasons for break-off, e.g. leg discomfort vs. breathless-
ness, provide additional insights [34].
Strengths
•Standardized protocols are available [35].
•Treadmill walking reflects an activity of daily living.
•Cycle ergometer is less prone to introduce movement
or noise artefacts into measurements than treadmill, and
electrocardiogram and blood pressure are generally eas-
ier to measure [35].
•Additional physiological and clinical variables, such as
peak O2 uptake, CO2 output, minute ventilation, heart
rate, dyspnoea, and leg discomfort can be determined in
parallel.
Limitations
•The workload not only depends on speed and inclina-
tion of the treadmill but also on the weight of the subject
and pacing strategy. Body weight has much less effect on
bicycle ergometry performance [30].
•Cycling is less closely related to the patient's activities
of daily living.
•Resources: Ergometers are relatively expensive, tread-
mills require much space.
•No MID has been established yet.
Physical Activity
Sensors for physical activity
The methods that are available to quantify physical activ-
ity in daily life include direct observation, assessment of
energy expenditure, and the use of physical activity ques-
tionnaires or motion sensors. In particular, motion sen-
sors are practical tools for clinical trials or practice.
Accelerometers are electronic devices that record energy
expenditure or mechanically assess movement. The
devices are usually worn on patients' arm or waist. Accel-
erometers read out stored data as movement intensity
and as quantity and can also provide data on body pos-
ture.
Strengths
•Accelerometers generate objective data by determina-
tion of quantity and intensity of body movements.
•Significant limitations of physical activity can already
b e  d e t e c t e d  i n  p a t i e n t s  w i t h  m o d e r a t e  C O P D  ( G O L D
stage II) [31].
Limitations
•Solid evidence for reliability, validity and responsiveness
for different types of accelerometers still has to be pro-
vided [26,31].
•Some activity sensors are poorly accepted by patients
[36].
•Variability in sensitivity among accelerometers of a
given model has been detected [37].
•Accelerometers may be sensitive to artefacts like car
vibrations [26].
•Activity sensors may actually fail to accurately capture
the inactive life style of patients with COPD [38].
•Physical activity patterns vary from day to day and
between week-days and weekend due to the patient's
health, or external factors [31]. In long-term studies,
another source of variability may be seasonal climate
changes, hours of daylight and weather [38].
•Observation bias: a greater level of activity may be
induced during the measurement period that results in
overestimation of the activity [39]. On the other hand,
underreporting bias may evolve from poor compliance
[26,39].
•No MID has been established yet.
Open questions and outlook
Exercise capacity is an important clinical outcome in
interventional trials of COPD, but it is still debatable
what is the most valid, reliable, and responsive measure-
ment of changes within subjects.
Physical activity may become a key outcome measure
not only in clinical trials of COPD, but also in rehabilita-
tion programs and for patients' self-management. EvenGlaab et al. Respiratory Research 2010, 11:79
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though the technical assessment of physical activity is
improving rapidly, not all new techniques have been
developed to the point where their clinical utility has
been validated.
Little is known about the agreement of exercise capac-
ity as measured using different methods. Therefore, indi-
rect comparisons of treatment effects on exercise
capacity are obscured by different methods of assessment
applied in various trials.
Dyspnoea
Relevance
For patients with COPD, dyspnoea is the most frequent
complaint for which they seek medical attention. How-
ever, dyspnoea is a subjective measure that poorly corre-
lates with objective assessments of lung function, exercise
capacity, and other outcomes [1].
Measures
Different approaches have been used to measure dysp-
noea in clinical trials, amongst which the BDI/TDI, Borg-
Scale, and MRC are applied most often (table 2).
Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/
TDI)
The BDI and TDI represent one of the most commonly
applied instruments for dyspnoea rating in clinical trials,
describing symptoms at a single point in time (e.g., base-
line (BDI)), and measuring changes in breathlessness
from this baseline state over time (TDI) [40].
BDI and TDI ratings are obtained in the course of an
interview conducted by an experienced observer, who
asks open-ended questions about the patient's experience
of breathlessness during everyday activities, which are
then translated into numerical values.
Strengths
•BDI and TDI ratings provide multi-dimensional mea-
surements of breathlessness (functional impairment,
magnitude of task, and magnitude of effort) related to
activities of daily living.
•A MID with a difference of 1 unit for the mean total
score being considered clinically meaningful is available
though it is mainly based on retrospective data analysis
[41,42].
Limitations
•Interviewer bias: Neither interviewer questions nor the
translation of patients' answers to ratings are standard-
ized, enforcing thorough interviewer training.
•Recall bias: The patient has to recall baseline state
(BDI) in order to answer questions regarding the TDI.
•Assessment bias: Interviewer blinding to patients' clin-
ical status is necessary to prevent assessment bias.
Medical Research Council (MRC) Scale
The MRC dyspnoea scale was developed as a simple and
standardised method of categorising disability in COPD
[4].
The patient selects a grade on the self-applied 5-point
instrument that describes everyday situations or activity
levels provoking breathlessness and impairment. A MID
has not been established.
Strengths
•The method has been widely used in the past [43-46].
Limitations
•A possible underestimation bias due to avoidance of
exertion has to be taken into account [47].
•The MRC is relatively insensitive to change, e.g. due to
therapeutic intervention [48,49].
•There are relatively scarce clinical data on validation,
responsiveness, and sensitivity [43].
Borg-Scale (CR-10)
The CR-10 or Borg-Scale has been developed primarily as
an objective tool to measure exertional dyspnoea in
COPD patients [50,51]. Although the 10-point category
ratio scale is easy to use, concise and detailed instructions
for patients are indispensable for appropriate application
[52]. Based on retrospective analysis, a MID for the Borg-
Scale in the range of 1 unit has been discussed [4].
Open Questions and Outlook
More research is needed to optimize and validate ques-
tionnaire items including direct patient involvement in
instrument generation to improve their utility in clinical
trials. Little is known about the impact of concomitant
disorders on outcomes, e.g. if disorders such as anxiety or
depression influence perceived dyspnoea and - if so - to
which extent those instruments applied today reflect that
influence. Furthermore, studies are needed to show
Table 2: Dyspnoea measurement scales
Type of scale Type of stimulus Items Administration
BDI/TDI multi-dimensional everyday activities 8/9 interview
MRC-Scale uni-dimensional everyday activities 1 self-administered by patient
Borg-Scale uni-dimensional under exertion 1 self-administered by patient
BDI: Baseline Dyspnoea Index; TDI: Transition Dyspnoea Index; MRC: Medical Research Council.Glaab et al. Respiratory Research 2010, 11:79
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which of the existing methodologies, e.g. questions or
word lists, should be preferred in the context of COPD.
Health Status
Relevance
Health-status is considered one of the main patient-
related outcomes in clinical trials. It is important to make
a distinction between quality of life (QoL), which is
unique to the individual, and health status measurement,
which is a standardized quantification of the impact of
disease [53].
Measures
Health-status as a concept of high complexity is assessed
indirectly and requires the application of specially
designed questionnaires (table 3).
St. George's Respiratory Questionnaire (SGRQ)
The SGRQ was originally developed to measure health
status in patients with respiratory disease, e.g. COPD or
asthma [54]. A COPD-specific version is available [55].
The SGRQ covers domains of symptoms (frequency
and severity of respiratory symptoms), activity (effects on
and adjustment of everyday activities), and psychosocial
impact, from which a total score with a possible maxi-
mum of 100 points is calculated.
The MID was assessed by various methods. Changes of
2 to 8 points were considered clinically meaningful, with
a value of 4 applied most often [56].
Strengths
•The SGRQ has been widely used in clinical trials as a
secondary endpoint to assess the effects of treatment and
management interventions on health status in COPD.
•It may be considered a quasi standard in clinical trials.
Limitations
•The instrument is time-consuming to implement and is
therefore of limited applicability in day-to-day clinical
practice.
•There is a trend bias due to non-poled questions (first
possible answer is usually "yes" and indicates worse
health-status) [57].
•The processing of missing answers is unsatisfactory. A
missing answer is considered as if the patient had
answered "no" (indicating better health-status) [57].
•SGRQ scores were shown to be influenced by subjects'
sex, age, education, and by comorbidities [58].
•Suitability of MID for individual patients as opposed
to patient group comparisons has yet to be shown.
•Linearity of differences between SGRQ values has not
been shown, especially not in different stages of severity.
Thus, it is unknown, whether a reduction in SGRQ total
score by 4 points (e.g. from 44 to 40) represents a subjec-
tive improvement in health status equivalent to a reduc-
tion from 64 to 60.
•There is little published empiric evidence supporting
the MID of four points [59].
Chronic Respiratory Disease Questionnaire (CRQ)
The CRQ measures physical-functional and emotional
limitations due to chronic lung diseases including COPD
[60]. It refers to activity-related dyspnoea with results
covering dyspnoea, fatigue, emotion, and mastery. The
questionnaire has primarily been applied in rehabilitation
trials of COPD patients [61].
The patient is asked to recall the five most important
activities that caused breathlessness over the past two
weeks. A total score as well as individual subscale scores
can be calculated. A difference of 0.5 for the mean
domain scores is considered clinically meaningful [62].
Strengths and limitations
A distinctive property of this instrument is the patient-
specific selection of five activities, which cause dyspnoea
for the individual patient. This way the instrument adapts
to the specific conditions of the patient and is sensitive to
treatment. On the other hand, the instrument is less suit-
able for inter-individual comparisons, as it mirrors indi-
vidual physical limitations. The questionnaire is not
interchangeable with other disease-specific instruments
and has not yet been shown to be responsive to long-term
disease progression.
Medical Outcomes Study Short Form-36 (SF-36)
The SF-36 is a generic health survey [63]. The patient is
asked to complete 36 items of the questionnaire. The
instrument allows the patient to self-assess psychic, phys-
ical, and social aspects of his or her quality of life.
Table 3: Health-status measurement instruments
Instrument Type Domains Items Administration
SGRQ disease-specific symptoms, activities, psychosocial impact 76 self-administered by 
the patient
CRQ disease-specific dyspnea, emotional function, fatigue, mastery 20 interview
SF-36 generic physical and social function, mental health, energy/
vitality, health perception, physical and mental role 
limitation, pain
36 self-administered by 
the patient
SGRQ: fSt. George's Respiratory Questionnaire; CRQ: Chronic Respiratory Disease Questionnaire; SF-36: Short Form 36.Glaab et al. Respiratory Research 2010, 11:79
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Strengths and limitations
SF-36 is the best-known questionnaire to measure health
status. The instrument has been shown to be discrimina-
tive, responsive to long-term disease progression, easy to
use, and has been validated in several languages. How-
ever, as a generic measure, it is considered less responsive
than disease-specific instruments in COPD and is not
consistently responsive to therapeutic effects. No MID
has been established yet.
Open questions and outlook
Further development of user-friendly, inexpensive instru-
ments to enable fast and easy health status assessment in
clinical trials as well as in daily practice is clearly
required. Ways to involve patients in questionnaire gen-
eration should be further explored. More information is
needed on the time course of health-status alterations
(e.g., induced by therapeutic intervention or secondary to
COPD exacerbations) and on the utility and efficacy of
health status instruments in less severe COPD.
Exacerbations
Relevance
Exacerbations of COPD indicate clinical instability and
progression of the disease and are associated with
increased morbidity, deterioration of comorbidities,
reduced health status, physical and physiologic deteriora-
tion and an increased risk of mortality [64,65]. The pre-
vention or reduction of exacerbations thus constitutes a
major treatment goal [1].
Measures
Verification by patient interview, healthcare databases or
prospectively from diary cards. Endpoints: frequency of
exacerbations, time to first exacerbation, severity and
duration of exacerbations.
Strenghts
•The event-based approach considers the need for sys-
temic corticosteroids and/or antibiotics or hospitalisation
due to an exacerbation. This definition may be more
robust and is relatively easy to record.
•The symptom-based definition of exacerbations con-
siders individual patient's perception of clinical status.
Limitations
•There is no standardized definition of an exacerbation,
making comparative evaluations of clinical study results
difficult [1,66].
•The symptom- and event-based approach involves
subjective and recall bias, particularly because patients
often have a poor understanding of exacerbation symp-
toms, resulting in substantial underreporting of exacer-
bations [67].
•The definition by use of health care resources is health
system specific and affected by many other factors (social
support, comorbidities, baseline health status, clinical
expert behaviour).
•Differential diagnoses to exacerbations such as pneu-
monia, heart failure, ischemic heart disease, pulmonary
embolism have to be taken into account.
•Seasonal variations in exacerbation frequency usually
require long-term studies of at least one year duration
[4,68].
•No MID has been established yet [4].
Open questions and outlook
There is a clear need to standardize the evaluation of the
onset, frequency, severity and duration of COPD exacer-
bations as well as to assess therapeutic effects on exacer-
bations in COPD. Given the potential clinical relevance of
even single exacerbations it appears quite difficult to
determine exactly what cut-off levels should be used in
terms of MIDs.
In addition, more work is needed to develop simple fea-
sible criteria for defining exacerbations in clinical prac-
tice and to analyse the multiple factors that contribute to
decisions to assess the severity stage of exacerbations. In
that context, the EXACT-PRO initiative began to develop
and evaluate a novel patient-reported outcome tool to
measure the rate, duration and severity of exacerbations
of COPD [69].
Multidimensional scoring systems - BODE
Relevance
So far the only multidimensional scoring system that has
gained broader acceptance is the BODE index which has
been developed as a prognostic marker for COPD
patients in an attempt to integrate not only the respira-
tory but also the systemic expressions of COPD in a sin-
gle grading system [70].
Measures
It comprises the four components nutritional state (BMI),
airflow limitation (Obstruction; FEV1), breathlessness
(MRC Dyspnoea scale), and Exercise capacity (6MWD,
distance walked in 6 min). Replacing the 6MWD with a
component for exacerbation frequency (BODEx index)
resulted in fully preserved power to predict the mortality
risk in a prospective observational study, while expanding
the BODE index with exacerbation frequency as a fifth
component (e-BODE index) did not further improve its
predictive power [71]. A truncated version of the BODE
index has been presented in which the exercise compo-
nent is omitted (BOD index) [72].
The validity of the BODE index as a prognostic marker
to predict mortality in COPD patients has recently been
challenged by a study demonstrating that the risk of all-
cause mortality over 3 years was considerably underesti-
mated by the BODE index in a population of severe
COPD patients, while on the contrary it was overesti-
mated in another population with milder disease, indicat-
ing that important predictors may still be missing in this
index [73]. Nevertheless, the BODE index has been usedGlaab et al. Respiratory Research 2010, 11:79
http://respiratory-research.com/content/11/1/79
Page 8 of 11
to assess therapeutic efficacy in interventional studies
investigating effects of lung volume reduction surgery
[74-76], pulmonary rehabilitation [77,78], and physical
training [79], but so far not in pharmacological interven-
tion trials.
Strengths
• T h e  BO D E  i n d e x  i n t e gr a t e s  d i f f e r e n t  f a c e ts  o f  C O P D
and the risks associated with significant comorbidities.
•It provides better power than that of its individual
components (e.g., FEV1) to predict mortality and future
exacerbations in patient populations with severe-to-very
severe COPD [70,80].
•Its assessment is straightforward.
Limitations
•The BODE index has not primarily been developed to
assess effects of therapeutic interventions and a MID has
not yet been defined.
•The BODE index has been optimized to predict one-
year mortality. The factors most critically affecting short-
term survival might differ from those determining sur-
vival over a longer term. Thus, its suitability for assess-
ment of patients with mild-to-moderate COPD is as yet
less validated.
•The FEV1 categories in the airway obstruction compo-
nent are not consistent with the current GOLD staging
system
•No published experience with BODE index as a clini-
cal outcome parameter in pharmacological intervention
studies is currently available.
Open questions and outlook
More widespread application of the BODE index as an
outcome parameter in clinical trials is currently ham-
pered by the lack of experience in pharmacological inter-
vention studies. Furthermore, its validity as a prognostic
marker in a population of patients affected by mild-to-
moderate COPD and its power to predict survival over
longer periods of time as yet have to be proven.
Mortality
Relevance
Long-term observations of large patient populations have
shown an increased risk for all-cause mortality in COPD
patients that rises proportionally to severity classes
[6,8,81,82]. Mortality can be recorded as all-cause mor-
tality and cause-specific mortality.
Strengths
•All-cause mortality is the most robust and reliable out-
come of clinical trials in COPD and is relatively easy to
follow-up [4,83,84].
Limitations
•Standardized methods to accurately define the cause of
death (e.g. respiratory versus cardiovascular mortality)
have not been established yet. Moreover, the careful anal-
ysis of the cause of death requires substantial effort.
•Retrospective mortality data may be confounded by
inherent statistical bias [85,86], and even prospective
studies are susceptible to bias due to missing follow-up of
withdrawals [86,87].
•Adequately powered mortality trials require high
patient numbers and extended study duration [3,84,88].
•It is as yet unclear, whether COPD-specific mortality is
increased in patients with milder forms of COPD (GOLD
stages I and II) [2,89].
•Mortality tends to be lower in participants of clinical
trials than is found in routine clinical care [90].
Open Questions and Outlook
One important issue is the statistical approach to analyse
the events of death. Intent-to-treat (ITT)-analyses, aim-
ing for complete follow-up of deaths are recommended
for unbiased comparison between treatment groups and
should be used preferentially as shown in major trials
[83,84,87].
For a confident, robust assessment, mortality should be
the primary outcome of a prospective trial. Clinical trials
evaluating death as a primary or secondary endpoint
should have a data safety monitoring board and an inde-
pendent adjudicating committee [3,4,91].
Conclusion
The understanding of the merits and limitations of cur-
rent methods for assessing physiological and clinical out-
comes of COPD is crucial for the interpretation and
design of clinical trials. Unfortunately, in contrast to
monitoring lung function, there is no gold standard for
measuring symptoms such as dyspnoea, health status,
exercise capacity, physical activity, or exacerbations, since
none of the available methods is optimal in all regards.
Accordingly, no single outcome measure can be recom-
mended for the assessment of treatment response in
COPD. More research is needed to improve and simplify
questionnaire-based markers or technologies to assess
outcomes such as physical activity or health status in
order to enable wider use in clinical trials as well as in pri-
mary care. A further step in that direction may be the
recent development of a COPD assessment test [92].
Implementation of MIDs may also help to assess which
changes of outcome markers can be considered clinically
relevant. However, MIDs hardly reflect the heterogeneity,
variability, and severity of COPD, as well as the numerous
confounding factors contributing to the clinical presenta-
tion of the disease.
Further, no biomarkers have been established yet to
reflect the inflammatory and destructive process in the
lung or to indicate responsiveness to treatment. However,
further research in this area is important as pulmonary
biomarkers - whether physiological or biochemical - are
urgently needed if clinical trials are to be shorter and
more discriminating than at present.Glaab et al. Respiratory Research 2010, 11:79
http://respiratory-research.com/content/11/1/79
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Finally, comorbid conditions such as cardiovascular
disease, anxiety and depressive disorders, lung cancer and
osteoporosis are often observed in COPD patients and
are likely to affect COPD outcomes. The impact of these
conditions together with the influences of concomitant
medication on COPD are variable and for many of them
still uncertain; nevertheless, they may alter COPD pheno-
type, disease progression and survival, and responses to
treatment. A systematic evaluation of comorbidities and
co-medication should be considered as part of COPD
management as they may influence the results of clinical
outcome measures.
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